Results 161 to 170 of about 1,121 (213)

Intravenous Immunoglobulin and Atherosclerosis

Clinical Reviews in Allergy & Immunology, 2005
Several inflammatory and immunological factors have been established as important contributors to atherogenesis. Among these, oxidized low-density lipoprotein (oxLDL) play a central role in the initiation and progression of atherosclerotic lesions. In atherosclerotic lesions, oxLDL was also found to co-localize with beta2-glycoprotein I (beta2-GPI ...
Eiji, Matsuura, Kazuko, Kobayashi, Katsumi, Inoue, Yehuda, Shoenfeld   +3 more
openaire   +2 more sources

Therapeutic intravenous immunoglobulins

Molecular Immunology, 2005
Intravenous immunoglobulins (IVIg) are concentrated formulations of human IgG prepared by industrial fractionation of large pools of individual plasma donations. IVIg were developed 20 years ago for the prophylaxis support of immunodeficient patients.
Réal, Lemieux, Renée, Bazin, Sonia, Néron   +2 more
openaire   +2 more sources

Intravenous immunoglobulin

Clinical Immunology and Immunopathology, 1986
The development of immunoglobulin preparations suitable for intravenous use that are safe, acceptable, and efficacious represents a major advance in the treatment of immunodeficient patients. Experience in the United States and elsewhere in the world indicates that the benefits of use in patients with well-documented humoral immunodeficiency far ...
openaire   +2 more sources

Immunomodulation by Intravenous Immunoglobulin

Journal of Pediatric Hematology/Oncology, 1990
In 1980, it was observed in a child with idiopathic thrombocytopenic purpura (ITP) that intravenous administration of pooled human immunoglobulin-G (IVIG) was followed by a rapid increase of the platelet count. Prompted by this finding, a pilot study and two prospective multicenter studies on children with ITP were organized.
P, Imbach, S, Barandun, H, Cottier, E, Gugler, A, Hassig, A, Morell, H, Wagner, H, Heiniger   +7 more
openaire   +2 more sources

Phannacokinetics of Intravenous Immunoglobulin in Neonates

Vox Sanguinis, 1989
Abstract. Intravenous immunoglobulin (IVIG) may be a therapeutic adjunct to antibiotic treatment of neonatal infections. We examined the pharmacokinetics and safety of IVIG in human neonates. Thirty neonates with suspected sepsis were randomly assigned either to a treatment (receiving either 250, 500, or 1,000 mg/kg of IVIG plus antibiotics) or ...
L E, Weisman, G W, Fischer, P, Marinelli, V G, Hemming, J R, Pierce, S M, Golden, C C, Peck   +6 more
openaire   +2 more sources

Immunomodulation With Intravenous Immunoglobulin

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1993
Since its introduction over a decade ago for the treatment of primary immunodeficiencies, intravenous immunoglobulin (IVIG) has demonstrated activity in a variety of autoimmune disorders. An understanding of IVIG's immunomodulatory effects provides the rationale for its potential application in the management of autoimmune disorders.
openaire   +2 more sources

Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin

Journal of Clinical Immunology, 1991
The proliferative responses and the immunoglobulin production of peripheral blood mononuclear cells to pokeweed mitogen were dose-dependently suppressed by sulfonated intravenous immunoglobulin (IVIG), polyethylene glycol-treated IVIG, pH 4-treated IVIG, or human gamma-globulin, but they were not or only slightly suppressed by human serum albumin or ...
N, Kondo, T, Ozawa, K, Mushiake, F, Motoyoshi, T, Kameyama, K, Kasahara, H, Kaneko, M, Yamashina, Y, Kato, T, Orii   +9 more
openaire   +2 more sources

Intravenous Immunoglobulin for Treatment of Pemphigus

Clinical Reviews in Allergy & Immunology, 2005
Pemphigus is a group of organ-specific, autoimmune, mucocutaneous blistering disorders with an established immunological basis. The goal of therapy in pemphigus is to eliminate or neutralize the pathogenic autoantibodies. As in other autoimmune diseases, early systemic therapy is important for control of the disease and for achieving sustained ...
Lehavit, Akerman, Daniel, Mimouni, Michael, David   +2 more
openaire   +2 more sources

Intravenous Immunoglobulin and Multiple Sclerosis

Clinical Reviews in Allergy & Immunology, 2005
Intravenous immunoglobulin (IVIg) has been used as an immunomodulatory therapy for the treatment of multiple sclerosis (MS). In the current review, we summarize the up-to-date data related to IVIg clinical trials in MS, and the suggested mechanisms of action by which IVIg modulates the relevant immunological pathways impaired in MS.
Anat, Achiron, Shmuel, Miron
openaire   +2 more sources

Intravenous Immunoglobulin and Dendritic Cells

Clinical Reviews in Allergy & Immunology, 2005
Intravenous immunoglobulin (IVIg) has increasingly been used for the treatment of autoimmune and systemic inflammatory diseases, and in supportive therapy of immunodeficient patients. Available clinical and experimental evidence suggests, however, that a wide spectrum of immune-mediated conditions could benefit from IVIg, including acute and chronic ...
Namita, Misra, Jagadeesh, Bayry, Jagadeesh, Bayary, Sooryasarathi, Dasgupta, Amal, Ephrem, Jean-Paul Duong Van, Huyen, Sandrine, Delignat, Gazzala, Hassan, Giuseppina, Caligiuri, Antonino, Nicoletti, Sebastien, Lacroix-Desmazes, Michel D, Kazatchkine, Srini V, Kaveri   +12 more
openaire   +2 more sources